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W: cost of waiting 
     The Black-Scholes pricing model [1] can be used to determine 
the value of a financial call option (an option to buy), but it is also 
the basis for several types of real options.  The value of the option, 
C, may be determined as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Where            is the cumulative standard normal distribution of dx 
 
     Option values are very sensitive to changes in the forecasted net 
revenues.  Many authors have pointed out that there is often value in 
delaying a decision, hence the value of a deferral option.  What few 
authors point out is that there is always a cost involved in the delay 
of a real engineering project.  If nothing else, projected revenues 
will be delayed, causing a decrease in their present value due to 
discounting.  Of course, the value of delaying may outweigh the 
cost of waiting, but deferral costs must not be ignored as they are in 
much of the literature.  The traditional view of a delay cost is to 
model it after dividends.  However, the dividend model is rarely the 
correct model because it fails to accurately describe the nature of 
lost cash flows.  Delay models must be matched to the details of the 
case being analyzed.  Including waiting costs is virtually a 
requirement for realistic industrial projects. 
 
     Considering the cost of waiting, the Black-Scholes equation can 
be modified for this adjustment.  The modified equations become: 
   
 
S: the present value of future net revenues  
X: investment costs 
t: the time horizon  
r: interest rate  
σ: volatility of the project‟s rate of return 
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     Traditional discounted cash flow techniques have been criticized 
because they to not capture the value of management flexibility.  
Real options analysis has been promoted as a means to more 
accurately capture the value of management flexibility, which exists 
in many real engineering projects.  The analysis of real options is 
based on financial option pricing theory that has been developed and 
discussed over the past two decades by many engineering economists 
and financial professionals.  The real options approach also has 
become one of several ways to analyze capital budgeting projects 
under uncertainty.   
Real Options Analysis 
Case Study:  
A Dementia Drug  
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     A drug company is seeking approval for a new drug product.  
The company is hoping for approval from the Food and Drug 
Administration (FDA) two years from now.  The drug will have 
patent protection for 10 years after FDA approval.  Once on the 
market, year-one net cash flow from sales is expected to be $8M 
(million), year two net revenues are expected to be $15M, and years 
three through ten are expected to be $22M.   
  
     The facility to produce the new drug will take two years to build 
at a cost of $38M with a $5M salvage value at the project horizon.  
There is a 90% chance that the FDA will approve the new drug.  
The project‟s hurdle rate is 25%, and the risk-free interest rate is 
5%.   
  
     If facility construction begins after FDA approval, initial sales 
will be delayed two years.  Because the patent limits the horizon for 
sales, two years of revenues are lost.  If facility construction begins 
now, it will be available to produce the drug upon FDA approval.  
However, if the FDA does not approve the drug, the unused $38M 
facility will have a salvage value of only $9M at the end of year 2.  
The cash flows are shown in Table 1.  The decision tree is shown in 
Figure 1. 
 
     The question facing the firm is whether the facility should be 
built now or delayed until after FDA approval?  Delays in approval 
can lead to shorter periods of product exclusivity.  While there may 
be value in delaying, there is a cost of waiting.  The NPV of the 
“Build Now” option is −$0.90 million, and the NPV of the “Build 
Later” option is −$0.36 million.  Traditional tools would indicate 
that the project should not be funded now or two years from now.   
 
Figure 1: Decision tree, dementia drug problem 
Table 1: Dementia drug investment options and cash flows 
Black-Scholes Pricing Model  
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Volatility 
     A limitation of the method is its exclusive focus on future cash 
flows.  While the volatility of a project is not equal to the volatility 
of its firm‟s stock, neither is it equal to the volatility of just one of 
its input parameters [3].  The technique is an improvement from 
previous methods, but is still limited in its scope. 
  
     Using the information and equations above, the volatility is first 
determined, using Monte Carlo analysis, to be 0.637 or 63.7%.  The 
Black-Scholes pricing model was then used to determine the option 
value of $5.27 million.  Use of binomial lattices provides a very 
similar option value estimate.  
  
     We previously [4] determined the volatility and option value 
using two additional methods.  Using the logarithmic cash flow 
method, often used in financial options, the volatility was 0.231, 
resulting in an option value of $0.45 million.  We also proposed a 
method based on IRR, where the volatility was 1.15 with the 
resulting option value of $11.3 million. 
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     The volatility recognizes that we are dealing with uncertainty.  
Volatility is defined as the standard deviation of the rate of return of 
the project.  The project volatility must be estimated, and this is the 
most difficult variable to forecast. 
  
     A method of identifying the volatility for real options using the 
logarithmic present value returns approach was presented by 
Copeland and Antikarov [2].  In this method, the estimated future 
cash flows are discounted (using the hurdle rate) to two present 
values: one for time 0 and another for time 1.  The time 0 value is 
treated as a static value, while the time 1 value is varied through 
Monte Carlo simulation.  The present value at the present time (t = 
0) is calculated as: 
     The present value at year 1 omits CF0 and discounts 
later cash flows by one less period, and it is calculated as: 
 
 
 
 
 
 
      
 
A logarithmic ratio of the present values of the cash flows 
is calculated as: 
 
 
 
 
 
 
  
  
EVPI 
    If perfect information were available on which chance branches 
would occur, then optimal decision choices could be made.  These 
optimum choices present the case where there is no loss of 
opportunity, and no loss of optimum payoff.  This optimum 
represents the expected project value with perfect information 
(EVwPI). The difference between the expected NPV and the 
expected value with perfect information (EVwPI) is the expected 
value of perfect information (EVPI). 
      
     The project has many variables, but to simplify the problem, we 
will assume that we know all of the values with certainty except for 
the decision of FDA approval.  This question is the primary source 
of risk in the project.  With this simplified problem all uncertainty 
is shown in the decision tree in Figure 1.   
  
     With perfect information, we will build if the FDA will approve 
the project, and we will not build if the FDA will not approve.   
  
     With perfect information, we cannot change the 90% and 10% 
probabilities of FDA approval, but we do get correct predictions of 
what will happen.  So 90% of the time FDA approves and we build, 
and 10% of the time FDA does not approve and we don‟t.  Thus, 
the EVwPI equals 90% of the NPV of the „build now‟ option ($2.58 
million) plus 10% of $0, or $2.32 million.  EVPI is calculated 
according to the following equation.  In this case the best decision 
without the perfect information has a present value of $0 since the 
decision is not to proceed. 
 
 
  
  
     The EVPI of the dementia drug project is $2.32 million 
EVPI = EVwPI – EVwithoutPI 
          = $2.32M − $0 = $2.32M 
 
Implied Volatility 
     We have four different estimates for the option value and EVPI, 
yet they all are supposed to be the same.  The numbers used for the 
techniques are the same, except for the volatility estimation.  We 
can assume that the option value equals the EVPI, and calculate the 
implied volatility using Goal Seek.  This finds the volatility where 
the Black-Scholes equation provides an option value of 2.32 
million.  This results in an implied volatility of 0.41, or 41%, which 
is a very reasonable number.  In fact, many pharmaceutical projects 
tend to run about 40%; this is a number that has been used by 
Merck to approximate small-molecule drug projects (based on 
stock proxies) [5].  The implied volatility of 41% is certainly more 
conservative, and probably more realistic, than the initial estimate 
of 63.7%. 
       
Two additional example problems were solved, providing a total of 
four different volatility techniques that are used in the literature.  
These included 1) management estimates with scenarios of given 
probabilities, 2) logarithmic cash flow method, similar to that used 
for financial options, and 3) logarithmic present value method as  
Future Work Implications 
1. EVPI is far less math 
intensive 
2. EVPI has fewer constraints 
3. Real options criticized for 
too high an option value 
4. EVPI provides a more 
conservative estimate 
5. Implication is that all 
volatility methods 
(including ours) are wrong 
1. Conclusion is that                
EVPI = Option Value 
2. Need to test on additional 
problems 
3. Work on mathematical 
proof of the equality 
4. Demonstrate major impact 
on real option valuation 
techniques 
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recommended by Copeland and 
Antikarov [2], and the internal 
rate of return method [4].  It 
was interesting to note that the 
EVPI provided a smaller option 
value estimate (and therefore 
smaller implied volatility) in 
five out of six analyses.  While this does not prove EVPI to be a 
more accurate method, it infers that it may be a more conservative 
method.  
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